Profitability Metrics

Gross Margin
89.56%
Operating Margin
88.23%
Net Margin
62.43%

Efficiency Metrics

Revenue per Expense Ratio
8.50
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
0.00%
Income Tax Rate
2.27%
EPS
1.2100000000

Balance Sheet Analysis

Current Ratio
0.03
Cash Ratio
0.01
Working Capital
$-99.57M
Debt to Equity
0.73
Debt to Assets
41.56%
Equity Ratio
57.01%

Cash Flow Analysis

Operating Cash Flow Ratio
35.25%
Free Cash Flow Ratio
35.25%
CapEx to Revenue
0.00%
Dividends Paid
$14.58M
Stock Buybacks
$142.73K
Total Shareholder Returns
$14.72M
Cash Position Change
8,851.5%

Key Takeaways (2023 FY)

  • Maintained positive net income growth despite revenue changes
  • Increased dividend payments by 2.87%
  • Increased R&D investment by 100.00%

Detailed Growth Metrics

Core Performance

Revenue
194.81%
Net Income
158.75%
EPS
158.74%
Operating Income
195.98%

Operational Efficiency

R&D Expenses
100.00%
SG&A Expenses
1,072.90%
Operating Cash Flow
33.11%
Free Cash Flow
33.11%

Balance Sheet Health

Assets
-3.23%
Debt
7.22%
Book Value per Share
-0.55%
Inventory
-335,100.00%

Shareholder Returns

Dividends per Share
2.87%
Shares Outstanding
-0.12%

Long Term Trends

3Y Revenue/Share
172.16%
5Y Revenue/Share
0.33%
3Y Dividend/Share
-12.63%
5Y Dividend/Share
-54.90%